PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 966615
PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 966615
Contact us about how to customize the report with add-on data.
Cephalosporin Market, By spectrum of antimicrobial activity (First, Second, Third, Fourth, and Fifth Generation), By Formulation (Oral and Injection), By Types (Prescription and OTC Drugs), By Application (Sexually Transmitted Disease, Respiratory Tract Infection, Skin Infection, Ear Infection, and Urinary Tract Infection), By Route of Administration, By Distribution Channel, and By Geography (EU, NA, APAC, LATAM, and MEA) - Analysis, Size, Share, Trends, & Forecast from 2021-2027.
The global Cephalosporin market was valued at USD 12.6 billion by 2019, growing with 4.8% CAGR during the forecast period, 2021-2027.
Cephalosporins are a broad group of antibiotics obtained from the mold Acremonium (formerly known as Cephalosporium). Cephalosporins are bactericidal and work in a comparable way to penicillins. They bind to and obstruct the activity of enzymes accountable for producing peptidoglycan, an essential bacterial cell wall component. They are termed broad-spectrum antibiotics because they are effective against a wide range of bacteria.
According to FDA, the cephalosporin class of drugs is essential in treating human diseases, such as pneumonia, skin and tissue infections, pelvic inflammatory disease, and other conditions.
The surge in the incidence of the population suffering from tonsillitis, pneumonia, bronchitis, and gonorrhea promotes market growth. Moreover, the rise in R&D activities to develop highly efficient & safe drugs, the rise in combination therapies, and increasing product launches coupled with rising approvals are the few factors propelling the growth. For instance, in May 2019, Sihuan Pharmaceutical Holdings Group Ltd., one of the largest cardio-cerebral vascular drug manufacturers in China, got its grant approval for "non-PVC solid-liquid double chamber bag for ceftazidime with sodium chloride injection, a third-generation cephalosporin.
Rising demand for antibacterial drugs further drives the growth of the global cephalosporin market. However, the side effects associated with these antibiotics, antibiotic resistance to cephalosporin, indefinite regulatory reforms are projected to impede the cephalosporin growth. On the other side, the discovery of advanced prospect molecules and the launch of innovative combination therapies to treat antibiotic-resistant microbial infections are likely to offer remunerative opportunities for the players.
Spectrum of Antimicrobial Activity Takeaway
Depending upon the spectrum of antimicrobial activity, the global business is categorized into first generation, second generation, third generation, fourth generation, and fifth generation. Among all, the third generation category occupied a lion's share in 2019 and anticipated to witness the remarkable growth during the analysis period, owing to the high broader spectrum of activity which is used for the treatment of Gram-negative bacillary meningitis. Furthermore, fifth-generation cephalosporins are projected to witness the highest growth in the prediction period.
In terms of formulation, the worldwide industry is categorized into oral and injection. The oral formulations are further bifurcated into tablets, capsules, and liquids. Injection-based formulations are the most preferred drug administration route due to quick drug delivery and high bioavailability. However, liquid formulations are also gaining traction in the market because of the notable advantages offered by them, such as effective dispensing of the drug; masking the unpleasant taste of certain other ingredients; oxidation, or microbial activity; easy swallowing for young or elderly.
By type, the cephalosporin industry is classified into Over-the-counter (OTC) drugs and prescription drugs. OTC products are expanding at an impressive growth rate over the forecast timeframe. Major industry trends such as Rx to OTC switch by pharmaceutical manufacturers, the rising tendency of people towards self-medication in emerging regions, and cost-saving advantage to citizens in Latin America and Asia-Pacific regions are strongly driving the regional as well as global market.
The increasing patent expiration rates result in switching from Rx to OTC by the companies as a counter-strategy. According to the Consumer Healthcare Products Association, in the U.S., approximately 106 ingredients, dosage strengths, and indications have undergone a switch from Rx to OTC status, translating to approximately 700 OTC products in the market.
Route of Administration Takeaway
Based on the route of administration, the worldwide industry is classified into oral and injection. The injection route has occupied a remarkable share in 2019 and is projected to grow at a considerable CAGR during the timeframe. The high growth of this market segment is attributed to the rising prevalence of chronic diseases, faster onset of action than other dosage forms like tablets and liquids as the medication enters the bloodstream immediately
In terms of application, the worldwide industry is categorized into sexually transmitted diseases, respiratory tract infection, skin infection, ear infection, urinary tract infection, and others (acute abdomen infection, meningitis, and pelvic infection). The respiratory tract infection segment generated the maximum revenue in 2019 and is foreseen to maintain its global dominance throughout the prediction period, as cephalosporins are used to treat both lower & upper respiratory tract infections.
According to the reports published by WHO in 2019, influenza leads to respiratory tract infections in 5-15% of the population and severe illness in 3-5 million people every year. Respiratory syncytial virus (RSV) is the most common cause of acute respiratory infection in children, causing almost 34 million episodes annually. Also, the sexually transmitted disease (STD) segment is projected to witness the highest CAGR owing to the growing STD's.
Distribution channels Takeaway
The worldwide industry is classified into online pharmacies, hospital pharmacies, and retail pharmacies in terms of distribution channels. The hospital pharmacies segment tends to dominate the market share during the outlook period. The growth is acknowledged majorly due to the growing count of patients admitted to hospitals because of the increasing prevalence of respiratory diseases and sexually transmitted infections.
The hospital pharmacies segment also focuses on preserving the standard of products related to this cancer for both out-patients and in-patients. The growing awareness about NSCLC and the developing healthcare infrastructures also aids in propelling hospital pharmacy growth with maximum profits.
Regionally, the overall industry is divided into North America, Middle East & Africa, Asia Pacific, Latin America, and Europe. North America is considered to be the most attractive market due to the rising prevalence of infectious diseases. For instance, according to the National Center for Health Statistics, the number of deaths due to pneumonia in the U.S. for the year 2017 is 49,157. Also, the number of emergency department visits with infectious and parasitic diseases as the primary diagnosis in the U.S. is around 4.1 million, showing lucrative opportunities for cephalosporin manufacturers.
On the flip side, Asia Pacific is projected to be the fastest-growing segment for the market. Developing countries such as India and China expect growth in such therapeutic drugs, accounting for the increasing diagnosis of pneumonia, sexually transmitted diseases, and tuberculosis. According to the reports published by MedIndia, about 6% of the adult population in India are affected by sexually transmitted diseases every year.
The emergence of the COVID-19 pandemic brought the world together to a standstill. However, the market for antibiotics, including cephalosporins, has seen a surge in the global market. In the research study, published in Clinical Infectious Diseases, researchers studied at data on more than 1,700 hospitalized coronavirus affected patients treated at 38 Michigan hospitals from March 13 to June 18 and observed that more than half received initial antibiotic therapy, with antibiotic treatment as high as 84% in some hospitals. But only a small fraction of those cases had bacterial co-infections. Subjects are being treated by various antibiotics globally, which are showing lucrative opportunities for the manufacturers.
Key Vendor Takeaway
Baxter International, Astellas, Abbott, Allergan Plc., Merck & Co. Inc., F.Hoffman-La Roche, Bristol-Myers Squibb, Lupin, GlaxoSmithKline, Basilea Pharmaceutical, Novartis AG, Pfizer, Inc., Sanofi, Teva Pharmaceutical Industries Ltd. among others.
The principal players are actively adopting various strategies such as acquisition, geographical expansion, development of new and efficient therapeutics, etc. to maintain their position in the market. Also, the companies are involved in the strategic development of new products, such as in 2017, Shionogi & Co. Ltd collaborated with F. Hoffmann-La Roche Ltd for the development and commercialization of baloxavir marboxi.
The market size and forecast for each segment and sub-segments has been considered as below:
Historical Year - 2016 to 2018
Base Year - 2019
Estimated Year - 2020
Projected Year - 2021 to 2027
Traders, Distributors, and Suppliers
Government and Regional Agencies
SCOPE OF THE REPORT
The scope of this report covers the market by its major segments, which include as follows:
GLOBAL CEPHALOSPORIN MARKET KEY PLAYERS
Basilea Pharmaceutica Ltd.
Bristol-Myers Squibb Company
Hoffman-La Roche ltd.
Merck & Co. Inc.
Teva Pharmaceutical Industries Ltd.
GLOBAL CEPHALOSPORIN MARKET BY SPECTRUM OF ANTIMICROBIAL ACTIVITY
GLOBAL CEPHALOSPORIN MARKET BY FORMULATION
GLOBAL CEPHALOSPORIN MARKET BY TYPES
GLOBAL CEPHALOSPORIN MARKET BY ROUTE OF ADMINISTRATION
GLOBAL CEPHALOSPORIN MARKET BY APPLICATION
Sexually Transmitted Disease
Respiratory Tract Infection
Urinary Tract Infection
Others (Acute Abdomen Infection, Meningitis, and Pelvic infection)
GLOBAL CEPHALOSPORIN MARKET BY FORMULATION
GLOBAL CEPHALOSPORIN MARKET, BY REGION
Rest of Europe
Rest of APAC
Rest of LATAM
The Middle East and Africa
United Arab Emirates
Rest of MEA
Types segment market share analysis, 2020 & 2027